The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Intermittent Claudication

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Intermittent Claudication


Psychiatry related information on Intermittent Claudication


High impact information on Intermittent Claudication


Chemical compound and disease context of Intermittent Claudication


Biological context of Intermittent Claudication


Anatomical context of Intermittent Claudication


Gene context of Intermittent Claudication


Analytical, diagnostic and therapeutic context of Intermittent Claudication


  1. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Roberts, D.H., Tsao, Y., McLoughlin, G.A., Breckenridge, A. Lancet (1987) [Pubmed]
  2. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Belch, J.J., Bell, P.R., Creissen, D., Dormandy, J.A., Kester, R.C., McCollum, R.D., Mizushima, Y., Ruckley, C.V., Scurr, J.H., Wolfe, J.H. Circulation (1997) [Pubmed]
  3. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., Pastore, M., Borrello, F., Belcastro, M., Picchi, A., Nami, R. Am. J. Med. (2003) [Pubmed]
  4. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Makin, A.J., Blann, A.D., Chung, N.A., Silverman, S.H., Lip, G.Y. Eur. Heart J. (2004) [Pubmed]
  5. Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system. Scheidegger, K.J., Nelissen-Vrancken, M.H., Leenders, P.J., Daemen, M.J., Smits, J.F., Wood, J.M. J. Hypertens. (1997) [Pubmed]
  6. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Girolami, B., Bernardi, E., Prins, M.H., Ten Cate, J.W., Hettiarachchi, R., Prandoni, P., Girolami, A., Büller, H.R. Arch. Intern. Med. (1999) [Pubmed]
  7. An investigation into factors associated with Helicobacter pylori infection. Woodward, M., Morrison, C., McColl, K. Journal of clinical epidemiology. (2000) [Pubmed]
  8. The relationship between free-living daily physical activity and the severity of peripheral arterial occlusive disease. Sieminski, D.J., Gardner, A.W. Vascular medicine (London, England) (1997) [Pubmed]
  9. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. Mahady, G.B. The Journal of cardiovascular nursing. (2002) [Pubmed]
  10. Exacerbation of intermittent claudication by propranolol. Fogoros, R.N. N. Engl. J. Med. (1980) [Pubmed]
  11. The US experience with cilostazol in treating intermittent claudication. Hiatt, W.R. Atherosclerosis. Supplements. (2005) [Pubmed]
  12. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lederman, R.J., Mendelsohn, F.O., Anderson, R.D., Saucedo, J.F., Tenaglia, A.N., Hermiller, J.B., Hillegass, W.B., Rocha-Singh, K., Moon, T.E., Whitehouse, M.J., Annex, B.H. Lancet (2002) [Pubmed]
  13. Ketanserin in intermittent claudication. Ramsay, L.E. Lancet (1986) [Pubmed]
  14. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication. De Cree, J., Leempoels, J., Geukens, H., Verhaegen, H. Lancet (1984) [Pubmed]
  15. Pentoxifylline and intermittent claudication. Spittel, J.A. Ann. Intern. Med. (1985) [Pubmed]
  16. Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Bagger, J.P., Helligsoe, P., Randsbaek, F., Kimose, H.H., Jensen, B.S. Circulation (1997) [Pubmed]
  17. Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy. Brevetti, G., di Lisa, F., Perna, S., Menabó, R., Barbato, R., Martone, V.D., Siliprandi, N. Circulation (1996) [Pubmed]
  18. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. Lazarous, D.F., Unger, E.F., Epstein, S.E., Stine, A., Arevalo, J.L., Chew, E.Y., Quyyumi, A.A. J. Am. Coll. Cardiol. (2000) [Pubmed]
  19. Predictors of death from aortic aneurysm among middle-aged men: the Whitehall study. Strachan, D.P. The British journal of surgery. (1991) [Pubmed]
  20. Fibrinolytic risk factor clustering and insulin resistance in healthy male relatives of men with intermittent claudication. Parry, D.J., Grant, P.J., Scott, D.J. The British journal of surgery. (2006) [Pubmed]
  21. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Lee, T.M., Su, S.F., Tsai, C.H., Lee, Y.T., Wang, S.S. Clin. Sci. (2001) [Pubmed]
  22. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. Dettelbach, H.R., Aviado, D.M. Journal of clinical pharmacology. (1985) [Pubmed]
  23. Activation of extracellular signal-regulated protein kinase in dorsal horn neurons in the rat neuropathic intermittent claudication model. Liu, Y., Obata, K., Yamanaka, H., Dai, Y., Fukuoka, T., Tokunaga, A., Noguchi, K. Pain (2004) [Pubmed]
  24. Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle. Pipinos, I.I., Shepard, A.D., Anagnostopoulos, P.V., Katsamouris, A., Boska, M.D. J. Vasc. Surg. (2000) [Pubmed]
  25. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. Aronow, W.S. J. Gerontol. A Biol. Sci. Med. Sci. (2001) [Pubmed]
  26. Thromboxane and neutrophil changes following intermittent claudication suggest ischaemia-reperfusion injury. Khaira, H.S., Nash, G.B., Bahra, P.S., Sanghera, K., Gosling, P., Crow, A.J., Shearman, C.P. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. (1995) [Pubmed]
  27. Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. Brevetti, G., De Caterina, M., Martone, V.D., Ungaro, B., Corrado, F., Silvestro, A., de Cristofaro, T., Scopacasa, F. Clin. Hemorheol. Microcirc. (2001) [Pubmed]
  28. Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. Pollex, R.L., Mamakeesick, M., Zinman, B., Harris, S.B., Hanley, A.J., Hegele, R.A. Cardiovascular diabetology [electronic resource]. (2005) [Pubmed]
  29. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. Tayebjee, M.H., Tan, K.T., MacFadyen, R.J., Lip, G.Y. J. Intern. Med. (2005) [Pubmed]
  30. Predictors of cognitive decline and mortality of aged people over a 10-year period. Tilvis, R.S., Kähönen-Väre, M.H., Jolkkonen, J., Valvanne, J., Pitkala, K.H., Strandberg, T.E. J. Gerontol. A Biol. Sci. Med. Sci. (2004) [Pubmed]
  31. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Brevetti, G., Perna, S., Sabbá, C., Martone, V.D., Condorelli, M. J. Am. Coll. Cardiol. (1995) [Pubmed]
  32. Drug treatment of intermittent claudication. Jacoby, D., Mohler, E.R. Drugs (2004) [Pubmed]
  33. A randomized, double-blind, placebo-controlled, crossover study to assess the immediate effect of sublingual glyceryl trinitrate on the ankle brachial pressure index, claudication, and maximum walking distance of patients with intermittent claudication. Walker, S.R., Tennant, S., MacSweeney, S.T. J. Vasc. Surg. (1998) [Pubmed]
  34. Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. Cassar, K., Bachoo, P., Ford, I., Greaves, M., Brittenden, J. J. Vasc. Surg. (2005) [Pubmed]
WikiGenes - Universities